Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

The Effects of Pharmacological Interventions on Smoking Cessation in People with Alcohol Dependence: A Systematic Review and Meta-analysis of Nine Randomized Controlled Trials

View through CrossRef
Background Pharmacotherapies are widely used for smoking cessation. However, their effect on smoking cessation for people with alcohol dependence remains unclear. Objective This study aimed to explore the effects of pharmacotherapies on smoking cessation for people with alcohol dependence. Methods Five electronic databases were searched in January 2021 for randomized controlled trials (RCTs) reporting the use of pharmacotherapies to promote smoking cessation in people with alcohol dependence. The risk of bias was assessed using the Cochrane tool. RevMan version 5.3 was used to perform meta-analyses of the changes in smoking behavior, and the GRADE approach was used to assess the certainty of the evidence. Results Nine RCTs involving 908 smokers with alcohol dependence were identified. Eight RCTs were published in the United States, and one was from Canada. The risk of bias was rated as low in three studies and unclear in the remaining six. The results of the meta-analysis showed that, compared with the placebo group, Varenicline had a significant effect on short-term smoking cessation (three RCTs, OR = 6.27, 95% CI: [2.49, 15.78], p < 0.05, very low certainty). Naltrexone had no significant effect on smoking cessation in short-term or long-term observations (three RCTs, OR = 0.99, 95% CI: [0.54, 1.81], p = 0.97, moderate certainty), and Topiramate had no significant effect (two RCTs, OR = 1.56, 95% CI: [0.67, 3.46], p > 0.05, low certainty). Only one trial reported that Bupropion had no effect on smoking cessation. Conclusion Varenicline may have a positive effect on smoking cessation in people with alcohol dependence. However, Naltrexone, Topiramate, and Bupropion seem to have no clear effect on increasing smoking abstinence among drinkers. The small number of studies and the low certainty of evidence indicate that caution is required in interpreting the results.
Title: The Effects of Pharmacological Interventions on Smoking Cessation in People with Alcohol Dependence: A Systematic Review and Meta-analysis of Nine Randomized Controlled Trials
Description:
Background Pharmacotherapies are widely used for smoking cessation.
However, their effect on smoking cessation for people with alcohol dependence remains unclear.
Objective This study aimed to explore the effects of pharmacotherapies on smoking cessation for people with alcohol dependence.
Methods Five electronic databases were searched in January 2021 for randomized controlled trials (RCTs) reporting the use of pharmacotherapies to promote smoking cessation in people with alcohol dependence.
The risk of bias was assessed using the Cochrane tool.
RevMan version 5.
3 was used to perform meta-analyses of the changes in smoking behavior, and the GRADE approach was used to assess the certainty of the evidence.
Results Nine RCTs involving 908 smokers with alcohol dependence were identified.
Eight RCTs were published in the United States, and one was from Canada.
The risk of bias was rated as low in three studies and unclear in the remaining six.
The results of the meta-analysis showed that, compared with the placebo group, Varenicline had a significant effect on short-term smoking cessation (three RCTs, OR = 6.
27, 95% CI: [2.
49, 15.
78], p < 0.
05, very low certainty).
Naltrexone had no significant effect on smoking cessation in short-term or long-term observations (three RCTs, OR = 0.
99, 95% CI: [0.
54, 1.
81], p = 0.
97, moderate certainty), and Topiramate had no significant effect (two RCTs, OR = 1.
56, 95% CI: [0.
67, 3.
46], p > 0.
05, low certainty).
Only one trial reported that Bupropion had no effect on smoking cessation.
Conclusion Varenicline may have a positive effect on smoking cessation in people with alcohol dependence.
However, Naltrexone, Topiramate, and Bupropion seem to have no clear effect on increasing smoking abstinence among drinkers.
The small number of studies and the low certainty of evidence indicate that caution is required in interpreting the results.

Related Results

Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Varenicline Versus Cytisine for Smoking Cessation in a Primary Care Setting: A Randomized Controlled Trial
Varenicline Versus Cytisine for Smoking Cessation in a Primary Care Setting: A Randomized Controlled Trial
Abstract Our study aims to implement a smoking cessation program using pharmacotherapy in a real-life setting — primary care practices in Croatia and Slovenia — and...
Problematyka wczesnego alkoholizmu
Problematyka wczesnego alkoholizmu
The Problem of Early Alcoholizm   The group of 50 repeatedly convicted recidivists, dealt with in this article, aged 38 on the average, deserves particular attention, first of all ...
Formerly Smoking and Currently Smoking Cancer Survivors’ View on Smoking Cessation – A Qualitative Study
Formerly Smoking and Currently Smoking Cancer Survivors’ View on Smoking Cessation – A Qualitative Study
Background Drastic life events, such as a cancer diagnosis, do not necessarily lead to a reduction in unhealthy and dysfunctional behaviors like smoking. Contin...
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
This review summarizes the evidence from six randomized controlled trials that judged the effectiveness of systematic review summaries on policymakers' decision making, or the most...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Evaluating the effect of smoking and its cessation on semen parameters
Evaluating the effect of smoking and its cessation on semen parameters
Our primary aim was to investigate the reversibility of the negative impact of smoking on male fertility. Secondarily, we studied the effect of both time after smoking cessation as...

Back to Top